BioScrip, Inc. [NASDAQ:BIOS]: Analyst Rating and Earnings
Equities traders often pay a significant amount of attention to what top market analysts have to say about a potential stock investment. In regards to BioScrip, Inc. [BIOS], the most recent average analyst recommendation we can read comes from the fiscal quarter ending in December. On average, stock market experts give BIOS an Outperform rating. Its stock price has been found in the range of 1.56 to 4.14. This is compared to its latest closing price of $2.08.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for BioScrip, Inc. [BIOS] is sitting at 1.86. This is compared to 1 month ago, when its average rating was 1.86.
For the quarter ending in Mar-19 BioScrip, Inc. [BIOS] generated $0.18 billion in sales. That’s 0.15% lower than the average estimate of $0.18 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep your eyes on this company’s next financial results, which are scheduled to be made public on Tue 6 Aug (In 82 Days).
Fundamental Analysis of BioScrip, Inc. [BIOS]
Now let’s turn to look at profitability: with a current Operating Margin for BioScrip, Inc. [BIOS] sitting at +2.45 and its Gross Margin at +30.95.
This company’s Return on Total Capital is 3.73, and its Return on Invested Capital has reached 1.50%. Its Return on Assets is -8.69.
Similarly, its Total Debt to Total Capital is 111.17, while its Total Debt to Total Assets stands at 86.43.
What about valuation? This company’s Enterprise Value to EBITDA is 18.15 and its Total Debt to EBITDA Value is 12.32. The Enterprise Value to Sales for this firm is now 1.03, and its Total Debt to Enterprise Value stands at 0.49.
Shifting the focus to workforce efficiency, BioScrip, Inc. [BIOS] earns $346,991 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 7.08 and its Total Asset Turnover is 1.19. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.38 and its Current Ratio is 1.63. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
BioScrip, Inc. [BIOS] has 130.70M shares outstanding, amounting to a total market cap of $271.86M. Its stock price has been found in the range of 1.56 to 4.14. At its current price, it has moved by -51.33% from its 52-week high, and it has moved 29.17% from its 52-week low.
This stock’s Beta value is currently 0.58, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 50.50. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is BioScrip, Inc. [BIOS] a Reliable Buy?
BioScrip, Inc. [BIOS] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.